Literature DB >> 29399390

CCL3 augments tumor rejection and enhances CD8+ T cell infiltration through NK and CD103+ dendritic cell recruitment via IFNγ.

Frederick Allen1, Iuliana D Bobanga2, Peter Rauhe3, Deborah Barkauskas3, Nathan Teich3, Caryn Tong3, Jay Myers3, Alex Y Huang1,3,4.   

Abstract

Inflammatory chemokines are critical contributors in attracting relevant immune cells to the tumor microenvironment and driving cellular interactions and molecular signaling cascades that dictate the ultimate outcome of host anti-tumor immune response. Therefore, rational application of chemokines in a spatial-temporal dependent manner may constitute an attractive adjuvant in immunotherapeutic approaches against cancer. Existing data suggest that the macrophage inflammatory protein (MIP)-1 family and related proteins, consisting of CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES), can be major determinant of immune cellular infiltration in certain tumors through their direct recruitment of antigen presenting cells, including dendritic cells (DCs) to the tumor site. In this study, we examined how CCL3 in a murine colon tumor microenvironment, CT26, enhances antitumor immunity. We identified natural killer (NK) cells as a major lymphocyte subtype that is preferentially recruited to the CCL3-rich tumor site. NK cells contribute to the overall IFNγ content, CD103+ DC accumulation, and augment the production of chemokines CXCL9 and CXCL10 for enhanced T cell recruitment. We further demonstrate that both soluble CCL3 and CCL3-secreting irradiated tumor vaccine can effectively halt the progression of established tumors in a spatial-dependent manner. Our finding implies an important contribution of NK in the CCL3 - CD103+ DC - CXCL9/10 signaling axis in determining tumor immune landscape within the tumor microenvironment.

Entities:  

Keywords:  CCL3; CD103+ dendritic cells; CD8+ T cells; CXCL10; CXCL9; interferon-gamma; natural killer cells

Year:  2017        PMID: 29399390      PMCID: PMC5790335          DOI: 10.1080/2162402X.2017.1393598

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  42 in total

1.  Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.

Authors:  Julie M Roda; Robin Parihar; Cynthia Magro; Gerard J Nuovo; Susheela Tridandapani; William E Carson
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

3.  Type 1 T-cell responses in chlamydial lung infections are associated with local MIP-1alpha response.

Authors:  Naihong Zhang; Zhaoe Wang; Xiaofei Tang; Haiping Wang; Hongzhao Li; Huanjun Huang; Hong Bai; Xi Yang
Journal:  Cell Mol Immunol       Date:  2010-07-12       Impact factor: 11.530

Review 4.  Biology of interleukin-10.

Authors:  Robert Sabat; Gerald Grütz; Katarzyna Warszawska; Stefan Kirsch; Ellen Witte; Kerstin Wolk; Jens Geginat
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-05       Impact factor: 7.638

5.  Transient Surface CCR5 Expression by Naive CD8+ T Cells within Inflamed Lymph Nodes Is Dependent on High Endothelial Venule Interaction and Augments Th Cell-Dependent Memory Response.

Authors:  David Askew; Charles A Su; Deborah S Barkauskas; R Dixon Dorand; Jay Myers; Rachel Liou; Joseph Nthale; Alex Y Huang
Journal:  J Immunol       Date:  2016-03-18       Impact factor: 5.422

6.  The β-catenin signaling pathway induces aggressive potential in breast cancer by up-regulating the chemokine CCL5.

Authors:  Rika Yasuhara; Tarou Irié; Kenya Suzuki; Terumasa Sawada; Noriko Miwa; Akiko Sasaki; Yuko Tsunoda; Seigo Nakamura; Kenji Mishima
Journal:  Exp Cell Res       Date:  2015-09-10       Impact factor: 3.905

7.  Induction of the genes for Cxcl9 and Cxcl10 is dependent on IFN-gamma but shows differential cellular expression in experimental autoimmune encephalomyelitis and by astrocytes and microglia in vitro.

Authors:  Sally L Carter; Marcus Müller; Peter M Manders; Iain L Campbell
Journal:  Glia       Date:  2007-12       Impact factor: 7.452

8.  Cross-talk between T cells and innate immune cells is crucial for IFN-gamma-dependent tumor rejection.

Authors:  Zhiguang Li; Felicia Pradera; Thomas Kammertoens; Bing Li; Shubai Liu; Zhihai Qin
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

9.  CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.

Authors:  C Monteagudo; J M Martin; E Jorda; A Llombart-Bosch
Journal:  J Clin Pathol       Date:  2006-03-07       Impact factor: 3.411

Review 10.  Crosstalk between Wnt/β-Catenin and NF-κB Signaling Pathway during Inflammation.

Authors:  Bin Ma; Michael O Hottiger
Journal:  Front Immunol       Date:  2016-09-22       Impact factor: 7.561

View more
  43 in total

1.  Patrolling Monocytes Control NK Cell Expression of Activating and Stimulatory Receptors to Curtail Lung Metastases.

Authors:  Prakash Babu Narasimhan; Tobias Eggert; Yanfang Peipei Zhu; Paola Marcovecchio; Melissa A Meyer; Runpei Wu; Catherine C Hedrick
Journal:  J Immunol       Date:  2019-11-25       Impact factor: 5.422

2.  Targeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity.

Authors:  Pan Yin; Liming Gui; Caihong Wang; Jingjing Yan; Min Liu; Lu Ji; You Wang; Bin Ma; Wei-Qiang Gao
Journal:  Mol Ther       Date:  2020-08-08       Impact factor: 11.454

Review 3.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

Review 4.  Basophils as a potential therapeutic target in cancer.

Authors:  Jicheng Zhang; Hanlin Yin; Qiangda Chen; Guochao Zhao; Wenhui Lou; Wenchuan Wu; Ning Pu
Journal:  J Zhejiang Univ Sci B       Date:  2021-12-15       Impact factor: 3.066

Review 5.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

6.  Suppressor of cytokine signaling 1 inhibits the maturation of dendritic cells involving the nuclear factor kappa B signaling pathway in the glioma microenvironment.

Authors:  M He; X Chen; M Luo; L Ouyang; L Xie; Z Huang; A Liu
Journal:  Clin Exp Immunol       Date:  2020-06-30       Impact factor: 4.330

7.  Pharmacologic Depletion of Microglia Increases Viral Load in the Brain and Enhances Mortality in Murine Models of Flavivirus-Induced Encephalitis.

Authors:  Scott Seitz; Penny Clarke; Kenneth L Tyler
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

Review 8.  Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment.

Authors:  Benedikt Jacobs; Veronika Gebel; Lukas Heger; Victoria Grèze; Hansjörg Schild; Diana Dudziak; Evelyn Ullrich
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

9.  Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma.

Authors:  Brittany J Poelaert; Svetlana Romanova; Shelby M Knoche; Madeline T Olson; Bailee H Sliker; Kaitlin Smits; Brittney L Dickey; Alexandra E J Moffitt-Holida; Benjamin T Goetz; Nuzhat Khan; Lynette Smith; Hamid Band; Aaron M Mohs; Donald W Coulter; Tatiana K Bronich; Joyce C Solheim
Journal:  J Control Release       Date:  2020-07-22       Impact factor: 9.776

10.  Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy.

Authors:  Tae Gun Kang; Hyo Jin Park; Jihyun Moon; June Hyung Lee; Sang-Jun Ha
Journal:  Immune Netw       Date:  2021-06-17       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.